UNIVERSITAS
GADJAH MADA
**Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada
Lupus Eritematosus Sistemik**
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

.

Abediazar, S. *et al.* (2019) 'Serum levels of CXCL10 and vitamin D in patients with lupus nephritis', *Iranian Journal of Kidney Diseases*, 13(6), pp. 380–388.

Abujam, B., Cheekatla, S. S. and Aggarwal, A. (2013) 'Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis', *Lupus*, 22(6), pp. 614–623. doi: 10.1177/0961203313484977.

Aga Lewelt (2015) '乳鼠心肌提取 HHS Public Access', *Physiology & behavior*, 176(3), pp. 139–148. doi: 10.1016/j.physbeh.2017.03.040.

Ameer, M. A. *et al.* (2022) 'An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management', *Cureus*, 14(10). doi: 10.7759/cureus.30330.

Annamayra, A. *et al.* (2020) 'The molecular mechanism of corticosteroids for Systemic Lupus Erythematosus Patient's treatment and its adverse effects', *Systematic Reviews in Pharmacy*, 11(2), pp. 249–254. doi: 10.5530/srp.2020.2.38.

Antonelli, A. *et al.* (2014) 'Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases', *Autoimmunity Reviews*. Elsevier B.V., 13(3), pp. 272–280. doi: 10.1016/j.autrev.2013.10.010.

Aringer, M. *et al.* (2019) '2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus', *Arthritis and Rheumatology*, 71(9), pp. 1400–1412. doi: 10.1002/art.40930.

Arora, S., Isenberg, D. A. and Castrejon, I. (2020) 'Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage', *Arthritis Care and Research*, 72(S10), pp. 27–46. doi: 10.1002/acr.24221.

Badsha, H. and Edwards, C. J. (2003) 'Intravenous pulses of methylprednisolone for systemic lupus erythematosus', *Seminars in Arthritis and Rheumatism*, 32(6), pp. 370–377. doi: 10.1053/sarh.2002.50003.

Bazsó, A. *et al.* (2015) 'The importance of glucocorticoid receptors in systemic lupus erythaematosus. A systematic review', *Autoimmunity Reviews*. Elsevier B.V., 14(4), pp. 349–351. doi: 10.1016/j.autrev.2014.12.007.

Bruce, I. N. *et al.* (2015) 'Factors associated with damage accrual in patients with systemic lupus erythematosus : results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort', *Annals of the Rheumatic Diseases*, 74, pp. 1706–1713. doi: 10.1136/annrheumdis-2013-205171.

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Brunner, H. I. *et al.* (2003) 'Item Weightings for the Systemic Lupus International Collaborating Clinics / American College of Rheumatology Disease Damage Index Using Rasch Analysis Do Not Lead to an Important Improvement', *Journal of Rheumatology*, 30, pp. 292–298.

Buckner, C. A. *et al.* (2016) 'We are IntechOpen , the world ' s leading publisher of Open Access books Built by scientists , for scientists TOP 1 %', *Intech*, 11(tourism), p. 13. Available at: https://www.intechopen.com/books/advanced-biometric-technologies/liveness-detection-in-biometrics.

Buttgereit, F. *et al.* (2002) 'Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology', *Annals of the Rheumatic Diseases*, 61(8), pp. 718–722. doi: 10.1136/ard.61.8.718.

Cardoso, C. R. L. *et al.* (2008) 'Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: A cohort study', *Lupus*, 17(11), pp. 1042–1048. doi: 10.1177/0961203308093829.

Catalina, M. D. *et al.* (2020) 'The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus', *Journal of Autoimmunity*. Elsevier, 110(November), p. 102359. doi: 10.1016/j.jaut.2019.102359.

Chan, W. K. Y. (2023) 'A Review on Childhood-onset Systemic Lupus Erythematosus', *RPN.000668*, 7(4), pp. 5–8. doi: 10.31031/RPN.2023.07.000668.

Cheng Wang K, Huie Liu P, Hiu Yu, K, Jin Ng C, Fa Chiu T, Y. C. S. (2017) 'Is initial C-reactive protein level associated with corticosteroid use in lupus erythematosus patients during a bacterial infection episode ?' Immunology Letters 185, pp. 84–89.

Condon, M. B. *et al.* (2013) 'Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids', *Annals of the Rheumatic Diseases*, 72(8), pp. 1280–1286. doi: 10.1136/annrheumdis-2012-202844.

Corsini, E. *et al.* (2018) 'Chemical-induced contact allergy: from mechanistic understanding to risk prevention', *Archives of Toxicology*. Springer Berlin Heidelberg, 92(10), pp. 3031–3050. doi: 10.1007/s00204-018-2283-z.

Czaja, A. J. (2014) 'Alimentary Pharmacology and Therapeutics Review article : chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets', (May). doi: 10.1111/apt.12825.

Davidson, A. (2012) 'The rationale for BAFF inhibition in systemic lupus erythematosus', *Current Rheumatology Reports*, 14(4), pp. 295–302. doi: 10.1007/s11926-012-0258-2.

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Demircin, G. *et al.* (2008) 'Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis', *Renal Failure*, 30(6), pp. 603–609. doi: 10.1080/08860220802132171.

Dominguez-gutierrez, P. R. *et al.* (2012) 'Effects of Treatment On the Expression of CCL2 and CXCL10 in Systemic Lupus Erythematosus Patients', pp. 1–3.

Dominguez-gutierrez, P. R. *et al.* (2014) 'Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone , mycophenolate mofetil , or hydroxychloroquine , except in a high STAT1 subset', *Arthritis Research & Therapy*. Arthritis Research & Therapy, 16(1), pp. 1–15. doi: 10.1186/ar4451.

Duan, J. H. *et al.* (2016) 'Expression of BAFF and BR3 in patients with systemic lupus erythematosus', *Brazilian Journal of Medical and Biological Research*, 49(3), pp. 3–7. doi: 10.1590/1414-431X20154853.

Duffau, P. *et al.* (2010) 'Platelet CD154 potentiates interferon-α secretion by plasmacytoid dendritic cells in systemic lupus erythematosus', *Science Translational Medicine*, 2(47). doi: 10.1126/scitranslmed.3001001.

El-gohary, A. *et al.* (2016) 'Serum and Urinary Interferon-Gamma-Inducible Protein 10 in Lupus Serum and Urinary Interferon-Gamma-Inducible Protein 10 in Lupus Nephritis', *Journal of Clinical Laboratory Analysis*, 30, pp. 1135–1138. doi: 10.1002/jcla.21993.

Elhefny, A. A. M. *et al.* (2019) 'Hazards of pulse steroid use in a cohort of Egyptian lupus nephritis patients', *Egyptian Rheumatologist*. Egyptian Society of Rheumatic Diseases, 41(4), pp. 277–281. doi: 10.1016/j.ejr.2018.12.001.

Enríquez-Merayo, E. and Cuadrado, M. J. (2023) 'Steroids in Lupus: Enemies or Allies', *Journal of Clinical Medicine*, 12(11), pp. 1–9. doi: 10.3390/jcm12113639.

Enriquez Merayo, E. *et al.* (2018) 'Can we treat systemic lupus erythematosus and other autoimmune diseases without oral steroids?', *Expert Review of Clinical Immunology*. Taylor & Francis, 14(11), pp. 877–879. doi: 10.1080/1744666X.2018.1527219.

Fanouriakis, A. *et al.* (2019) '2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus', *Annals of the Rheumatic Diseases*, 78(6), pp. 736–745. doi: 10.1136/annrheumdis-2019-215089.

Fayyaz, A. *et al.* (2015) 'Haematological manifestations of lupus', *Lupus Science and Medicine*, 2(1). doi: 10.1136/lupus-2014-000078.

Fragoso-Loyo, H. *et al.* (2013) 'Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus', *Rheumatology (United Kingdom)*, 52(12), pp. 2218–2222. doi: 10.1093/rheumatology/ket294.

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Fresneda Alarcon, M., McLaren, Z. and Wright, H. L. (2021) 'Neutrophils in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus: Same Foe Different M.O.', *Frontiers in Immunology*, 12(March). doi: 10.3389/fimmu.2021.649693.

Fung, W. A., Su, J. and Touma, Z. (2017) 'Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis : Results from a Single Lupus Cohort', *BioMed Research International*, 2017.

Furie, R. *et al.* (2011) 'A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus', *Arthritis and Rheumatism*, 63(12), pp. 3918–3930. doi: 10.1002/art.30613.

Gao, J. *et al.* (2020) 'Role of Chemokine (C-X-C Motif) Ligand 10 (CXCL10) in Renal Diseases', *Mediators of Inflammation*, 2020. doi: 10.1155/2020/6194864.

Gauthier, M. *et al.* (2017) 'Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias', *JCI Insight*, 2(13), pp. 1–17. doi: 10.1172/jci.insight.94580.

Geneva-Popova, M. G. *et al.* (2022) 'A Study of IFN-α-Induced Chemokines CCL2, CXCL10 and CCL19 in Patients with Systemic Lupus Erythematosu', *Life*, 12(2). doi: 10.3390/life12020251.

Gensous, N. *et al.* (2017) 'Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review', *Arthritis Research & Therapy*. Arthritis Research & Therapy, 19(1), p. 238. doi: 10.1186/s13075-017-1442-6.

Goilav, B. and Putterman, C. (2016) *HHS Public Access*. doi: 10.1016/j.semnephrol.2015.08.005.The.

Green, D. S., Young, H. A. and Valencia, J. C. (2017) 'Current prospects of type II interferon γ signaling & autoimmunity', *Journal of Biological Chemistry*, 292(34), pp. 13925–13933. doi: 10.1074/jbc.R116.774745.

Gustavson, D. E. and Miyake, A. (2016) '乳鼠心肌提取 HHS Public Access', *Cognition Emotion Journal*, 30(7), pp. 1289–1303. doi: 10.1016/j.semarthrit.2019.03.010.Glucocorticoids.

Han, B. K. *et al.* (2020) 'Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus', *Lupus Science and Medicine*, 7(1), pp. 1–6. doi: 10.1136/lupus-2020-000382.

Hannah, J. R. and Cruz, D. P. D. (2019) 'Pulmonary Complications of Systemic Lupus Erythematosus', *Seminars in Respiratory and Critical Care Medicine*, 40(2), pp. 227–234.

Hari pankaj (2004) 'Indian Pediatrics', *indian Pediatrics*. New Delhi: indian

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Pediatrics 2004, 41, pp. 993–1000. Available at: http://indianpediatrics.net/may2008/may-410-412.htm.

He, Z. *et al.* (2022) 'Comprehensive analysis of epigenetic modifications and immune-cell infiltration in tissues from patients with systemic lupus erythematosus', *Epigenomics*, 14(2), pp. 81–100. doi: 10.2217/epi-2021-0318.

Hessels, A. C. *et al.* (2019) 'Clinical outcome in anti-neutrophil cytoplasmic antibody-associated vasculitis and gene variants of 11β-hydroxysteroid dehydrogenase type 1 and the glucocorticoid receptor', *Rheumatology (United Kingdom)*, 58(3), pp. 447–454. doi: 10.1093/rheumatology/key319.

Hosmer andLemeshow (2013) 'Epdf.Pub_Applied-Logistic-Regression-Wiley-Series-in-Probab.Pdf'.

Hrycek, E. *et al.* (2013) 'Serum levels of selected chemokines in systemic lupus erythematosus patients', *Rheumatology International*, 33(9), pp. 2423–2427. doi: 10.1007/s00296-012-2393-5.

Hu Xiaoyu, Ping Li Wai, Meng Charis, I. L. B. (2003) 'Inhibition of IFN-gamma Signaling by Glucocorticoid', *The Journal of Immunology*, 170, pp. 4833–4839.

Illescas-Montes, R. *et al.* (2019) 'Infectious processes and systemic lupus erythematosus', *Immunology*, 158(3), pp. 153–160. doi: 10.1111/imm.13103.

Isenberg, D. A., Morrow, W. J. W. and Snaith, M. L. (1982) 'Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus', *Annals of the Rheumatic Diseases*, 41(4), pp. 347–351. doi: 10.1136/ard.41.4.347.

J.A., R. *et al.* (2018) 'Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations', *Arthritis Research and Therapy*. Arthritis Research & Therapy, pp. 1–10.

Jara, L. J. *et al.* (2005) 'methylprednisolone in severe neurological manifestations in', pp. 620–625. doi: 10.1136/ard.2004.025528.

Ji, L. *et al.* (2022) 'Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal . A analysis systematic review and meta- -'. doi: 10.1136/lupus-2021-000603.

Kamhieh-Milz, J. *et al.* (2018) 'Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP)', *Clinical Immunology*. Elsevier Inc, 188, pp. 74–80. doi: 10.1016/j.clim.2017.12.010.

Kandane-Rathnayake, R. *et al.* (2021) 'Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: A longitudinal, multinational study', *Rheumatology (Bulgaria)*, 60(11), pp. 5185–5193. doi: 10.1093/rheumatology/keab217.

Kaplan, M. J. (2011) 'Neutrophils in the pathogenesis and manifestations of SLE.',

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Nature reviews. Rheumatology. United States, 7(12), pp. 691–699. doi: 10.1038/nrrheum.2011.132.

Khalifa.A.S, T. K. . (1993) 'No Tit.צוכle', *Acta Haematol*, 90, pp. 125–129. Available at: https://www.ptonline.com/articles/how-to-get-better-mfi-results.

Khan, M. A. H. *et al.* (2019) 'Epoxyeicosatrienoic acid analog EET-A blunts development of lupus nephritis in mice', *Frontiers in Pharmacology*, 10(MAY), pp. 1–10. doi: 10.3389/fphar.2019.00512.

Kong, K. O. *et al.* (2009) 'Enhanced expression of interferon-inducible protein- 10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus', pp. 134–140. doi: 10.1111/j.1365-2249.2009.03880.x.

Koupenova, M. *et al.* (2018) 'Circulating platelets as mediators of immunity, inflammation, and thrombosis', *Circulation Research*, 122(2), pp. 337–351. doi: 10.1161/CIRCRESAHA.117.310795.

Lambers, W. M. *et al.* (2021) 'Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus', *Journal of Rheumatology*, 48(6), pp. 847–851. doi: 10.3899/jrheum.200726.

Lee, J. S. *et al.* (2018) 'Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea', *Medicine (United States)*, 97(26), pp. 1–5. doi: 10.1097/MD.0000000000011138.

Li, Y. *et al.* (2015) 'Behavioral deficits are accompanied by immunological and neurochemical changes in a mouse model for neuropsychiatric lupus (NP-SLE)', *International Journal of Molecular Sciences*, 16(7), pp. 15150–15171. doi: 10.3390/ijms160715150.

Liu, J., Zhang, X. and Cao, X. (2022) 'Dendritic cells in systemic lupus erythematosus: From pathogenesis to therapeutic applications', *Journal of Autoimmunity*. Elsevier Ltd, 132(June), p. 102856. doi: 10.1016/j.jaut.2022.102856.

Liu, M. *et al.* (2018) 'Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity', *Clinical Rheumatology*. Clinical Rheumatology, 37(10), pp. 2675–2684. doi: 10.1007/s10067-018-4138-7.

Liu, Y. *et al.* (2022) 'Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: A review', *Frontiers in Cell and Developmental Biology*, 10(September), pp. 1–11. doi: 10.3389/fcell.2022.998328.

Ma, K. *et al.* (2019) 'Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus', *International Journal of Molecular Sciences*, 20(23). doi:

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

10.3390/ijms20236021.

Magro-Checa, C. *et al.* (2016) 'Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives', *Drugs*, 76(4), pp. 459–483. doi: 10.1007/s40265-015-0534-3.

Man, B. L., Mok, C. C. and Fu, Y. P. (2014) 'Neuro-ophthalmologic manifestations of systemic lupus erythematosus: A systematic review', *International Journal of Rheumatic Diseases*, 17(5), pp. 494–501. doi: 10.1111/1756-185X.12337.

Mathian, A. *et al.* (2015) 'Regulatory T cell responses to high-dose methylprednisolone in active systemic lupus erythematosus', *PLoS ONE*, 10(12), pp. 1–17. doi: 10.1371/journal.pone.0143689.

Mejía-Vilet, J. M. and Ayoub, I. (2021) 'The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug', *Frontiers in Medicine*, 8(February), pp. 1–11. doi: 10.3389/fmed.2021.622225.

Migita, K. *et al.* (2018) 'Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis', *Medicine (United States)*, 97(50), pp. 1–9. doi: 10.1097/MD.0000000000013450.

Mikdashi, J. and Nived, O. (2015) 'Measuring disease activity in adults with systemic lupus erythematosus : the challenges of administrative burden and responsiveness to patient concerns in clinical research', *Arthritis Research & Therapy*. Arthritis Research & Therapy, pp. 1–10. doi: 10.1186/s13075-015-0702-6.

Mikolajczyk, T. P. *et al.* (2021) 'Pharmacology & Therapeutics Role of in fl ammatory chemokines in hypertension', 223. doi: 10.1016/j.pharmthera.2020.107799.

Möckel, T. *et al.* (2021) 'B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)', *Autoimmunity Reviews*, 20(2), pp. 10–17. doi: 10.1016/j.autrev.2020.102736.

Morais, S. A., Vilas Boas, A. and Isenberg, D. A. (2015) 'B-cell survival factors in autoimmune rheumatic disorders', *Therapeutic Advances in Musculoskeletal Disease*, 7(4), pp. 122–151. doi: 10.1177/1759720X15586782.

Moretti, M. *et al.* (2023) 'Systemic lupus erythematosus: one year in review 2023', *Clinical and Experimental Rheumatology*, 41(4), pp. 765–773. doi: 10.55563/clinexprheumatol/zf4daj.

Mu, Q. *et al.* (2017) 'Control of lupus nephritis by changes of gut microbiota'. Microbiome, pp. 1–12. doi: 10.1186/s40168-017-0300-8.

Murayama, M. A. *et al.* (2023) 'Chemokines and chemokine receptors as promising targets in rheumatoid arthritis', (February), pp. 1–17. doi:

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

10.3389/fimmu.2023.1100869.

Nagai, T. *et al.* (2005) 'Anti – Ribosomal P Protein Antibody in Human Systemic Lupus Erythematosus Up-Regulates the Expression of Proinflammatory Cytokines by Human Peripheral Blood Monocytes', 52(3), pp. 847–855. doi: 10.1002/art.20869.

Narváez, J. *et al.* (2018) 'Primary respiratory disease in patients with systemic lupus erythematosus : data from the Spanish rheumatology society lupus registry (RELESSER) cohort'. Arthritis Research & Therapy, 8, pp. 1–10.

Navarra, S. V. *et al.* (2011) 'Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial', *The Lancet*. Elsevier Ltd, 377(9767), pp. 721–731. doi: 10.1016/S0140-6736(10)61354-2.

Netti, G. S. *et al.* (2019) 'Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy', *Journal of Immunology Research*, 1, pp. 1–12. doi: 10.1155/2019/8483650.

Nishioji, K. *et al.* (2001) 'Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes', *Clin Exp Immunol*, 123(2), pp. 271–279.

Nived, O. *et al.* (2002) 'High predictive value of the Systemic Lupus International Collaborating Clinics / American College of Rheumatology damage index for survival in systemic lupus erythematosus', *Journal of Rheumatology*, 29(7), pp. 1398–1400.

Nomura, A. *et al.* (2019) 'Unique primed status of microglia under the systemic autoimmune condition of lupus-prone mice', *Arthritis Research and Therapy*. Arthritis Research & Therapy, 21(1), pp. 1–17. doi: 10.1186/s13075-019-2067-8.

Ocejo, A. and Correa, R. (2023) 'Methylprednisolone.', in. Treasure Island (FL).

Odler, B. *et al.* (2017) 'CCL21 and IP-10 as blood biomarkers for pulmonary involvement in systemic lupus erythematosus patients.', *Lupus*. England, 26(6), pp. 572–579. doi: 10.1177/0961203316668418.

Ohmura, K. (2021) 'Which is the best SLE activity index for clinical trials?', *Modern Rheumatology*. Taylor & Francis, 31(1), pp. 20–28. doi: 10.1080/14397595.2020.1775928.

Oke, V. *et al.* (2017) 'IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)', *Arthritis Research and Therapy*. Arthritis Research & Therapy, 19(1), pp. 1–12. doi: 10.1186/s13075-017-1344-7.

Oku, K. and Atsumi, T. (2018) 'Systemic lupus erythematosus: nothing stale her infinite variety', *Modern Rheumatology*. Taylor & Francis, 28(5), pp. 758–765. doi:

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

10.1080/14397595.2018.1494239.

Oon, S., Wilson, N. J. and Wicks, I. (2016) 'Targeted therapeutics in SLE : emerging strategies to modulate the interferon pathway'. Nature Publishing Group, 5(5), pp. e79-10. doi: 10.1038/cti.2016.26.

P, J. E., Idha, A. and Suryana, B. P. P. (2015) 'Megadose Methylprednisolone On Total Lymphocyte Count and Disease Activity In Systemic Lupus Erythematosus (SLA)', 51(1), pp. 40–44.

Pan, L. *et al.* (2020) 'Immunological pathogenesis and treatment of systemic lupus erythematosus', *World Journal of Pediatrics*. Childrens Hospital, Zhejiang University School of Medicine, 16(1), pp. 19–30. doi: 10.1007/s12519-019-00229-3.

Perhimpunan Reumatologi Indonesia (2018) *Pedoman Diagnosis dan Pengelolaan Gout Rekomendasi Perhimpunan Reumatologi Indonesia*.

Porta, S. *et al.* (2020) 'Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues', *Journal of Clinical Medicine*, 9(9), pp. 1–13. doi: 10.3390/jcm9092709.

Puapatanakul, P., Chansritrakul, S. and Susantitaphong, P. (2019) 'Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis : A Systematic Review and Meta-Analysis', *Int J Mol Sci.*, 20, pp. 1–14.

Qian, H. *et al.* (2020) 'Associations of Platelet Count with Inflammation and Response to Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis', *Frontiers in Pharmacology*, 11(November), pp. 1–10. doi: 10.3389/fphar.2020.559593.

Qin, B. *et al.* (2015) 'Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) were Useful Markers in Assessment of Inflammatory Response and Disease Activity in SLE patients', 7595(September). doi: 10.3109/14397595.2015.1091136.

Ramsey-goldman, R. *et al.* (2017) 'Cell-bound complement activation products in SLE', *Lupus Science and Medicine*, pp. 1–8. doi: 10.1136/lupus-2017-000236.

Rekomendasi Perhimpunan Reumatologi Indonesia (2019) 'Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik ISBN Perhimpunan Reumatologi Indonesia', in, p. 9.

Riedel, J. H. *et al.* (2023) 'Glucocorticoids target the CXCL9/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury', *JCI Insight*, 8(1). doi: 10.1172/jci.insight.160251.

Rivera, M. F. C. and Dans, L. F. (2022) 'Systemic Lupus Erythematosus in Filipino

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Children: A 10-year Retrospective Analysis of Mortality, Morbidity and Survival', *Acta Medica Philippina*, 56(9), pp. 98–106. doi: 10.47895/amp.v56i9.5380.

Rose, T. *et al.* (2013) 'IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.', *Annals of the rheumatic diseases*. England, 72(10), pp. 1639–1645. doi: 10.1136/annrheumdis-2012-201586.

Rovin, B. H. *et al.* (2005) 'Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy', *Kidney International*, 68(2), pp. 747–759. doi: 10.1016/s0085-2538(15)50895-8.

Rovin, B. H. *et al.* (2019) 'A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis', *Kidney International*, 95(1), pp. 219–231. doi: 10.1016/j.kint.2018.08.025.

Ruiz-Irastorza, G. *et al.* (2014) 'Prednisone in lupus nephritis: How much is enough?', *Autoimmunity Reviews*. Elsevier B.V., 13(2), pp. 206–214. doi: 10.1016/j.autrev.2013.10.013.

Ruiz-Irastorza, G. *et al.* (2016) 'Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus', *Clinical and Experimental Rheumatology*, 34(3), pp. 466–472.

Ruiz-Irastorza, G. *et al.* (2019) 'Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts', *Autoimmunity Reviews*. Elsevier, 18(9), p. 102359. doi: 10.1016/j.autrev.2019.102359.

Ruiz-Irastorza, G. (2020) 'Can we effectively treat lupus and reduce the side-effects of glucocorticoids?', *The Lancet Rheumatology*. Elsevier Ltd, 2(1), pp. e3–e5. doi: 10.1016/S2665-9913(19)30132-8.

Ruiz-Irastorza, G. *et al.* (2020) 'Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus', *Lupus*, 29(10), pp. 1155–1167. doi: 10.1177/0961203320930099.

Ruiz-Irastorza, G., Danza, A. and Khamashta, M. (2018) 'Glucocorticoid use and abuse in SLE', *Rheumatology (United Kingdom)*, 51(7), pp. 1145–1153. doi: 10.1093/rheumatology/ker410.

Sahebari Maryam, Rezaieyazdi, Z. *et al.* (2023) 'Expression pattern of glucocorticoid receptor alpha gene and associations with clinicolaboratory features in patients with systemic lupus erithematosus', *Caspian Journal of Internal Medicine 2023;14(3):*, 2023(3), pp. 470–478. doi: 10.22088/cjim.14.3.470.

Schäfer, V. S. *et al.* (2018) 'Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

clinical and laboratory parameters of disease activity', *Clinical Rheumatology*. Clinical Rheumatology, 37(7), pp. 1835–1844. doi: 10.1007/s10067-018-4093-3.

Scofield RH (2020) 'Systemic Lupus Erythematosus (SLE) Genetics What to Read Next on Medscape', *Genomic Medicine*.

Seet, D. *et al.* (2021) 'Cognitive Dysfunction in Systemic Lupus Erythematosus: Immunopathology, Clinical Manifestations, Neuroimaging and Management', *Rheumatology and Therapy*. Springer Healthcare, 8(2), pp. 651–679. doi: 10.1007/s40744-021-00312-0.

Sellam, J. *et al.* (2007) 'Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus', *Annals of the Rheumatic Diseases*, 66(6), pp. 790–797. doi: 10.1136/ard.2006.065656.

Shaqura, M. *et al.* (2016) 'Membrane-bound glucocorticoid receptors on distinct nociceptive neurons as potential targets for pain control through rapid non-genomic effects', *Neuropharmacology*, 111, pp. 1–13. doi: 10.1016/j.neuropharm.2016.08.019.

Shiozawa, F. *et al.* (2004) 'Research article Enhanced expression of interferon-inducible protein 10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL / lpr mice', *Arthritis Research & Therapy*, 6(1), p. R 78. doi: 10.1186/ar1029.

Shobha, V. *et al.* (2023) 'Severe thrombocytopenia is associated with high mortality in systemic lupus erythematosus — analysis from Indian SLE Inception cohort for Research (INSPIRE)', *Clinical Rheumatology*. Springer International Publishing, (0123456789). doi: 10.1007/s10067-023-06641-5.

Sim, T. M., Mak, A. and Tay, S. H. (2022) 'Insights into the role of neutrophils in neuropsychiatric systemic lupus erythematosus: Current understanding and future directions', *Frontiers in Immunology*, 13(August), pp. 1–15. doi: 10.3389/fimmu.2022.957303.

Sinha, A. and Bagga, A. (2008) 'Pulse Steroid Therapy', *Indian Journal of Pediatrics*, 75, pp. 1057–1066.

Smulski, C. R. and Eibel, H. (2018) 'BAFF and BAFF-receptor in B cell selection and survival', *Frontiers in Immunology*, 9(OCT), pp. 1–10. doi: 10.3389/fimmu.2018.02285.

Stohl, W. (2017) 'Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)', *Expert Review of Clinical Immunology*. Taylor & Francis, 13(6), pp. 623–633. doi: 10.1080/1744666X.2017.1291343.

Stojan, G. and Petri, M. (2017) 'HHS Public Access', *Curr Treatm Opt Rheumatol*, 3(3), pp. 164–172. doi: 10.1007/s40674-017-0069-8.The.

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Strehl, C. *et al.* (2019) 'Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System', *Frontiers in immunology*, 10(July), p. 1744. doi: 10.3389/fimmu.2019.01744.

Suso, J. P. *et al.* (2018) 'Profile of BAFF and its receptors' expression in lupus nephritis is associated with pathological classes', *Lupus*, 27(5), pp. 708–715. doi: 10.1177/0961203317739132.

Thanou, A. *et al.* (2019) 'Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures', *Lupus Science and Medicine*, 6(1), pp. 1–6. doi: 10.1136/lupus-2019-000365.

Touma, Z. and Gladman, D. D. (2017) 'Current and future therapies for SLE : obstacles and recommendations for the development of novel treatments', *Lupus Science and Medicine*, pp. 1–11. doi: 10.1136/lupus-2017-000239.

Touma, Z., Gladman, D. D. and Urowitz, M. B. (2013) 'Clinical Measures, Metrics, and Indices', in *Dubois' Lupus Erythematosus and Related Syndromes: Eighth Edition*. Eighth Edi. Elsevier Inc., pp. 563–581. doi: 10.1016/B978-1-4377-1893-5.00046-7.

Tsai, Y. *et al.* (2014) 'CD8 + Treg Cells Associated with Decreasing Disease Activity after Intravenous Methylprednisolone Pulse Therapy in Lupus Nephritis with Heavy Proteinuria', *PLoS ONE*, 9(1), pp. 1–12. doi: 10.1371/journal.pone.0081344.

Tseng, C. E. *et al.* (2006) 'The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial', *Arthritis and Rheumatism*, 54(11), pp. 3623–3632. doi: 10.1002/art.22198.

Tsokos, G. C. *et al.* (2016) 'New insights into the immunopathogenesis of systemic lupus erythematosus', *Nature Reviews Rheumatology*. Nature Publishing Group, 12(12), pp. 716–730. doi: 10.1038/nrrheum.2016.186.

Vazquez, J. T. *et al.* (2019) 'Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus', *Arthritis Rhematol*, 71(Suppl 10), pp. 1–5.

Vincent, F. B. *et al.* (2014) 'The BAFF/APRIL system in SLE pathogenesis', *Nature Reviews Rheumatology*. Nature Publishing Group, 10(6), pp. 365–373. doi: 10.1038/nrrheum.2014.33.

Vincent, F. B. *et al.* (2019) 'Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus', 8, pp. 1–11. doi: 10.1002/cti2.1047.

Wardhani, R. and Sufiawati, I. (2018) 'Oral Manifestations of Systemic Lupus

UNIVERSITAS GADJAH MADA
Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada Lupus Eritematosus Sistemik
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

Erythematous and Its Comprehensive Management: Two Case Reports', *Majalah Kedokteran Bandung*, 50(1), pp. 61–66. doi: 10.15395/mkb.v50n1.1234.

Wenzel, J. (2019) 'Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies.', *Nature reviews. Rheumatology*. United States, 15(9), pp. 519–532. doi: 10.1038/s41584-019-0272-0.

Wilkinson, C. *et al.* (2020) 'The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: A post hoc meta-analysis', *Arthritis Research and Therapy*. Arthritis Research & Therapy, 22(1), pp. 1–11. doi: 10.1186/s13075-020-02177-0.

Wong, E. B. *et al.* (2015) 'B Cell–Intrinsic CD84 and Ly108 Maintain Germinal Center B Cell Tolerance', *The Journal of Immunology*, 194(9), pp. 4130–4143. doi: 10.4049/jimmunol.1403023.

Woo, J. M. P. *et al.* (2022) 'The role of environmental exposures and gene – environment interactions in the etiology of systemic lupus erythematous', pp. 755–778. doi: 10.1111/joim.13448.

Yan, S. *et al.* (2015) 'Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL / MpSlac-lpr mice', *Nature Publishing Group*. Nature Publishing Group, 36(11), pp. 1367–1376. doi: 10.1038/aps.2015.76.

Yoshio, T. *et al.* (2016) 'IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus', *Lupus*, 25(9), pp. 997–1003. doi: 10.1177/0961203316629556.

You, Y. *et al.* (2015) 'Methylprednisolone attenuates lipopolysaccharide-induced Fractalkine expression in kidney of Lupus-prone MRL / lpr mice through the NF-kappaB pathway', *BMC Nephrology*. BMC Nephrology, pp. 1–8. doi: 10.1186/s12882-015-0145-y.

Zahr, Z. A. *et al.* (2013) 'Predictors of corticosteroid tapering in SLE patients: The Hopkins Lupus Cohort', *Lupus*, 22(7), pp. 697–701. doi: 10.1177/0961203313490434.

Zaki, D. S. D. *et al.* (2019) 'Study of B Cell Activating Factor (BAFF) and BAFF-R in Systemic Lupus Erythematosus Patients', 9(6), pp. 203–209. doi: 10.5923/j.ajmms.20190906.06.

Zeher, M. *et al.* (2011) 'Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis', *Lupus*, 20(14), pp. 1484–1493. doi: 10.1177/0961203311418269.

Zeid, M. M. H. *et al.* (2018) 'Study of urinary interferon gamma-induced protein 10 (IP-10) and urinary soluble CD 25 (sCD25) as markers of lupus nephritis and

UNIVERSITAS
GADJAH MADA
**Formulasi Klinis Dan Laboratoris Untuk Menentukan Respon Terapi Metilprednisolon Dosis Pulse Pada
Lupus Eritematosus Sistemik**
Ayu Paramaiswari, Prof.Dr.dr Nyoman Kertia,SpPD-KR.; Dr.dr Umi Solekhah Intansari,M Kes,SpPK(K)
Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/

their relation to histological class', *Alexandria Journal of Medicine*. Alexandria University Faculty of Medicine, 54(4), pp. 647–653. doi: 10.1016/j.ajme.2018.11.001.

Zhang, P. and Lu, Q. (2018) 'Genetic and epigenetic influences on the loss of tolerance in autoimmunity', *Cellular and Molecular Immunology*. Nature Publishing Group, 15(6), pp. 575–585. doi: 10.1038/cmi.2017.137.

Zhang, R. *et al.* (2019) 'Increased expression of hub gene CXCL10 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus', *Experimental and Therapeutic Medicine*, 18, pp. 4067–4075. doi: 10.3892/etm.2019.8013.

Zollars, E. *et al.* (2015) 'BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year', *Lupus Science and Medicine*, 2(1), pp. 1–7. doi: 10.1136/lupus-2014-000063.